Curaleaf Holdings Inc
TSX:CURA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (26.7), the stock would be worth CA$4.95 (24% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 21.6 | CA$4 |
0%
|
| 3-Year Average | 26.7 | CA$4.95 |
+24%
|
| 5-Year Average | 26.7 | CA$4.95 |
+24%
|
| Industry Average | 14.4 | CA$2.67 |
-33%
|
| Country Average | 16.7 | CA$3.09 |
-23%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Curaleaf Holdings Inc
TSX:CURA
|
3.1B CAD | 21.6 | -9.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 51.6 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 23.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 21.1 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 15.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 18.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10.5 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 17.2 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 10.6 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Curaleaf Holdings Inc
Glance View
Curaleaf Holdings Inc., a prominent player in the burgeoning cannabis market, has carved out a significant niche for itself by fully integrating its operations from cultivation to distribution. Founded in 2010, the Massachusetts-based company has rapidly grown to become one of the largest cannabis retailers in the United States. With a keen eye on the complex regulatory landscape, Curaleaf has strategically expanded its footprint across multiple states, adapting to various state laws and regulations. Their operational strategy hinges on vertical integration, meaning they control every stage of the cannabis supply chain. This allows Curaleaf not only to maintain high product quality and consistency but also to maximize margins by reducing costs and gaining efficiencies at all levels of production and retailing. Generating revenue through a combination of wholesale and retail sales, Curaleaf has established a range of products including cannabis flower, oils, edibles, and topical treatments, catering to both medical and recreational customers. The company's retail outlets, spanning across multiple states, are crucial in driving sales, where knowledgeable staff guide customers through intricate product offerings aimed at satisfying diverse consumer needs. Meanwhile, Curaleaf’s wholesale division supplies products to other retail outlets, expanding its market reach and solidifying its brand presence. The synergy between its retail prowess and wholesale operations has allowed Curaleaf to sustain steady revenue growth, positioning it well in a highly competitive and rapidly evolving industry.